低分子肝素联合黄芪治疗围生期心肌病临床研究

【摘要】 目的观察低分子肝素联合黄芪治疗围生期心肌病的临床疗效。方法选择平顶山市第四人民医院2001年6月~2006年12月住院105例围生期心肌病患者,随机分为两组。对照组50例,给常规治疗;治疗组55例,给低分子肝素注射液5000U、12h一次、皮下注射,黄芪注射液30ml,加5%GS250ml内静脉点滴,每日一次,连用7天。结果治疗1周后治疗组与对照组的有效率分别为98%与82%,差异有显著性(P﹥0.05)。3个月后随访治疗组发生栓塞率明现低于对照组。结论低分子肝素联合黄芪治疗围生期心肌病效果好,并发栓塞率低,不良反应少,可作为治疗围生期心肌病的常规用药。更多还原

【Abstract】 Objective To observe clinical curative effect of low molicular weight heparin(LMWH) and astragaloside that use to cure the peripartum cardiomyopathy(PPCM). Methods Pick 105 cases of PPCM in 4th People’s Hosipital of Pingding Shan from 2001-6 to 2006-12. Divide them into 2 groups randomly. 50 cases in compare group,take the normal therapy; 55 cases in therapy group, sucutaneous inject LMWH 500U, every 12 hours, Intravenous Nitroglycerin astragaloside 30ml together with 5%GS250ml once a day, for 7 days constantly. Result After one week’s therapy, the effctive percent of therapy group is 98%, the effctive percent of compare group is 82%, which is obviously different(p>0.05).After 3 weeks, the percent of embolus of therapy group is obviously lower than compare group. Conclusion low molicular weight heparin(LMWH) and astragaloside has good curative effect on treating cardiomyopathy(PPCM), and embolus is seldom found,with little unhealthy refelect. So they can be taken in the cilincal therapy.更多还原